Tyrosine kinase inhibitors and reduced-dose chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia

References

• Ottmann OG. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2013;2011(2):231–237.
   Google Scholar
• Fielding AK, Zakout GA. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2013;2011(2):231–237.
   Google Scholar
• Fielding AK, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489–4496. doi:10.1182/blood-2009-01-199380
   PubMed Web of Science ®Google Scholar
• Ravandi F, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Advances. 2016;1(3):250–259. doi:10.1182/bloodadvances.2016001495
   PubMed Web of Science ®Google Scholar
• Salami K, et al. Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Hematol Oncol Stem Cell Ther. 2013;6(1):34–41. doi:10.1016/j.hemonc.2013.03.001
   PubMedGoogle Scholar
• Rousselot P, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774–782. doi:10.1182/blood-2016-02-700153
   PubMed Web of Science ®Google Scholar
• Chalandon Y, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–3719. doi:10.1182/blood-2015-02-627935
   PubMed Web of Science ®Google Scholar
• Vignetti M, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the gruppo italiano malattie ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676–3678. doi:10.1182/blood-2006-10-052746
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (Vol. 2). International agency for research on cancer Lyon; 2008.
   Google Scholar
• Thomas DA, et al. Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12):4396–4407. doi:10.1182/blood-2003-08-2958
   PubMed Web of Science ®Google Scholar
• Lou Y, et al. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Med. 2017;11(2):229–238. doi:10.1007/s11684-017-0506-y
   PubMed Web of Science ®Google Scholar
• Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35–44. doi:10.1002/sim.4780030106
   PubMed Web of Science ®Google Scholar
• Fielding AK, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843–850. doi:10.1182/blood-2013-09-529008
   PubMed Web of Science ®Google Scholar
• Fielding AK. How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 2010;116(18):3409–3417. doi:10.1182/blood-2010-01-242750
   PubMed Web of Science ®Google Scholar
• Foà R, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–6528. doi:10.1182/blood-2011-05-351403
   PubMed Web of Science ®Google Scholar
• Chiaretti S, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101(12):1544–1552. doi:10.3324/haematol.2016.144535
   PubMed Web of Science ®Google Scholar
• Martinelli G, et al. First report of the gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2017;130(Supplement 1):99–99. doi:10.1182/blood.V130.Suppl_1.99.99
   Google Scholar
• Silva WF, et al. Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort. Leuk Res. 2021;110:106666. doi:10.1016/j.leukres.2021.106666
   PubMed Web of Science ®Google Scholar
• Kim DY, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746–756. doi:10.1182/blood-2015-03-636548
   PubMed Web of Science ®Google Scholar
• Shen S, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome–positive acute lymphoblastic leukemia. JAMA Oncol. 2020;6(3):358–366. doi:10.1001/jamaoncol.2019.5868
   PubMed Web of Science ®Google Scholar
• Ehsani M, et al. Cost-analysis of treatment of pediatrics acute lymphoblastic leukemia based on ALL-BFM protocol. Pediatr Blood Cancer. 2018;65:S113–S113.
   Web of Science ®Google Scholar
• Rae C, et al. Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood. Eur J Cancer Care (Engl). 2014;23(6):779–785. doi:10.1111/ecc.12173
   PubMed Web of Science ®Google Scholar
• Ghatak N, Trehan A, Bansal D. Financial burden of therapy in families with a child with acute lymphoblastic leukemia: report from north India. Support Care Cancer. 2016;24(1):103–108. doi:10.1007/s00520-015-2757-y
   PubMed Web of Science ®Google Scholar
• Tong WH, et al. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. Haematologica. 2013;98(5).
   PubMed Web of Science ®Google Scholar
• Kaul S, et al. A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia. Cancer Med. 2016;5(2):221–229. doi:10.1002/cam4.583
   PubMed Web of Science ®Google Scholar
• DiNofia AM, et al. Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. Cancer Med. 2018;7(1):3–12. doi:10.1002/cam4.1206
   PubMed Web of Science ®Google Scholar
• O'Connor D, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014;124(7):1056–1061. doi:10.1182/blood-2014-03-560847
   PubMed Web of Science ®Google Scholar
• Marwaha RK, et al. Pattern of mortality in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(5):366–369. doi:10.1097/MPH.0b013e3181e0d036
   PubMed Web of Science ®Google Scholar
• Sulis ML, et al. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(5):e26952. doi:10.1002/pbc.26952
   PubMed Web of Science ®Google Scholar
• Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Cancer Network. 2012;10(11):1412–1445. doi:10.6004/jnccn.2012.0146
   PubMed Web of Science ®Google Scholar
• Faiz M, Iqbal QJ, Qureshi A. High prevalence of BCR-ABL fusion transcripts with poor prognostic impact among adult ALL patients: report from pakistan. Asia Pac J Clin Oncol. 2011;7(1):47–55. doi:10.1111/j.1743-7563.2010.01370.x
   PubMed Web of Science ®Google Scholar
• Malagola M, Papayannidis C, Baccarani M. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. Ann Hematol. 2016;95(5):681–693. doi:10.1007/s00277-016-2617-y
   PubMed Web of Science ®Google Scholar
• Chalandon Y, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–3719. doi:10.1182/blood-2015-02-627935
   PubMed Web of Science ®Google Scholar
• F., et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Advances. 2016;1(3):250–259. doi:10.1182/bloodadvances.2016001495
   PubMed Web of Science ®Google Scholar
• Wang J, et al. Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(4):741–750. doi:10.1016/j.bbmt.2017.12.777
   PubMed Web of Science ®Google Scholar
• Ravandi F, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158–4164. doi:10.1002/cncr.29646
   PubMed Web of Science ®Google Scholar
• Ravandi F, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214–1221. doi:10.1182/blood-2012-11-466482
   PubMed Web of Science ®Google Scholar